Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects

British Journal of Clinical Pharmacology

Volumn 76, Issue 5, 2013, Pages 776-786

  Frost, Charles ^a   Nepal, Sunil ^a   Wang, Jessie ^a   Schuster, Alan ^a   Byon, Wonkyung ^b   Boyd, Rebecca A ^b   Yu, Zhigang ^a   Shenker, Andrew ^a,c   Barrett, Yu Chen ^a   Mosqueda Garcia, Rogelio ^a,d   Lacreta, Frank ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b PFIZER INC   (United States)

^c GLAXOSMITHKLINE   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Anticoagulant thrombolytic drugs; Apixaban; Cardiovascular pharmacology; Coagulation fibrinolysis; Pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; APIXABAN; CREATINE KINASE; INFUSION FLUID; PLACEBO;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APPLICATION SITE BLEEDING; AREA UNDER THE CURVE; ARTICLE; BLEEDING TIME; BLOOD CLOTTING TIME; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FOLLOW UP; HEMATURIA; HUMAN; HUMAN EXPERIMENT; INTERNATIONAL NORMALIZED RATIO; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; PARALLEL DESIGN; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RISK ASSESSMENT; SIDE EFFECT; SINGLE DRUG DOSE; SKIN BRUISING; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ANTICOAGULANT/THROMBOLYTIC DRUGS; APIXABAN; CARDIOVASCULAR PHARMACOLOGY; COAGULATION/FIBRINOLYSIS; PHARMACOKINETICS;

ADMINISTRATION, ORAL; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; PYRAZOLES; PYRIDONES; YOUNG ADULT;

EID: 84878952383     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12106     Document Type: Article

References (34)

1. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e419S-e494S.
2. Hawkins D. Limitations of traditional anticoagulants. Pharmacotherapy 2004; 24: 62S-65.
3. Palareti G, Manotti C, DAngelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Leali N, Poggi M, Legnani C, Musolesi S, Coccheri S. Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy). Thromb Haemost 1997; 78: 1438-1443.
4. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002; 45: 1757-1766.
5. Kaiser B. Factor Xa - a promising target for drug development. Cell Mol Life Sci 2002; 59: 189-192.
6. Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, Wong PC, Rendina AR, Luettgen JM, Knabb RM, He K, Xin B, Wexler RR, Lam PY. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4, 5, 6, 7-tetrahydro-1H-pyrazolo[3, 4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007; 50: 5339-5356.
7. Roehrig S, Straub A, Pohlmann J, Lampe T, Pernerstorfer J, Schlemmer KH, Reinemer P, Perzborn E. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1, 3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005; 48: 5900-5908.
8. Wong PC, Quan ML, Crain EJ, Watson CA, Wexler RR, Knabb RM. Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics. J Pharmacol Exp Ther 2000; 292: 351-357.
9. Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 2007; 5: (Suppl. 1): 60-64.
10. Ieko M, Tarumi T, Takeda M, Naito S, Nakabayashi T, Koike T. Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis. J Thromb Haemost 2004; 2: 612-618.
11. Wong PC, Crain EJ, Watson CA, Wexler RR, Lam PY, Quan ML, Knabb RM. Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. J Thromb Thrombolysis 2007; 24: 43-51.
12. Wong PC, Crain EJ, Xin B, Wexler RR, Lam PY, Pinto DJ, Luettgen JM, Knabb RM. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008; 6: 820-829.
13. Jiang X, Crain EJ, Luettgen JM, Schumacher WA, Wong PC. Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro. Thromb Haemost 2009; 101: 780-782.
14. Luettgen JM, Knabb RM, He K, Pinto DJ, Rendina AR. Apixaban inhibition of factor Xa: microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma. J Enzyme Inhib Med Chem 2011; 26: 514-526.
15. Wong PC, Watson CA, Crain EJ. Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. J Thromb Haemost 2008; 6: 1736-1741.
16. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817.
17. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek E, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser S, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon J, Pais P, Parkhomenko A, Verheugt F, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
18. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361: 594-604.
19. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-815.
20. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487-2498.
21. Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 6: 1313-1318.
22. Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, Reeves RA, LaCreta F. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2013; 75: 476-487.
23. Barrett YC, Wang Z, Knabb RM. A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors. Clin Appl Thromb Hemost 2012 Apr 2 [Epub ahead of print].
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Text Revision. Washington, DC: APA, 2000.
25. Schwartz S, Dahl J, Ellefson M, Ahlquist D. The 'HemoQuant' test: a specific and quantitative determination of heme (hemoglobin) in feces and other materials. Clin Chem 1983; 29: 2061-2067.
26. Perrier D, Gibaldi M. General derivation of the equation for time to reach a certain fraction of steady state. J Pharm Sci 1982; 71: 474-475.
27. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-295.
28. Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, Maxwell BD, Chen SY, He K, Goosen TC, Humphreys WG, Grossman SJ. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010; 38: 448-458.
29. Horton JD, Bushwick BM. Warfarin therapy: evolving strategies in anticoagulation. Am Fam Physician 1999; 59: 635-646.
30. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5: 2368-2375.
31. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104: 1263-1271.
32. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Lindahl TL. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011; 9: 133-139.
33. Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 2010; 32: 673-679.
34. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, Le FL, Rohde G, Martinoli JL. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107: 379-387.